• Explore /
  • Poster
  • / Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.

Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.

Abstract Poster

Authors

David Quinn

David I. Quinn

USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA

David I. Quinn , Tian Zhang , Howard Gurney , Gurjyot K. Doshi , Patrick Wayne Cobb , Francis Parnis , Jae-Lyun Lee , Se Hoon Park , Andrey Semenov , Wayne Yen-Hwa Chang , Thomas Powles , Shuyan (Sabrina) Wan , Christian Heinrich Poehlein , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT03142334

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS712)

DOI

10.1200/JCO.2018.36.6_suppl.TPS712

Abstract #

TPS712

Poster Bd #

L19

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: Neal D. Shore

First Author: Christian Marth

First Author: Ashish M. Kamat